CHV Churchill Ventures Ltd

Canada House Wellness Group Inc. (“Canada House” or the “Company”) (CSE:CHV), building on its newly awarded Sales License, has announced a major restructuring and future rebranding of its business to highlight and differentiate its premium products and services.

An experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy products and services, Canada House is aligning its businesses under three verticals: Canada House Clinics (CHC), Canada House Grow (CHG), and its new retail arm - Canada House Retail (CHR). Each division clearly defines and communicates its competitive offering in the marketplace while delivering on the promise of Quality Cannabis and Quality Care across all touchpoints.

“Our newly developed brand demonstrates our commitment to providing leading Cannabinoid Therapy services, unique industry leading production practices, and now through Canada House Retail, a clear strategy for the recreational and adult use market,” says Chris Churchill-Smith, CEO. “CHR will initially house our Edmonton Dispensary and will be responsible for product development to address the robust Canadian recreational market and the discerning cannabis consumer’s interest to have access to high-quality, craft Cannabis.”

CHC will continue to focus on independent medical cannabis clinics that help patients renew their lives with medical cannabis, cannabinoid therapy education, and patient-specific treatment protocols, while Knalysis, with its sophisticated cannabis patient management software and data analytics, will continue to improve on treatment efficacies.

The Canada House Grow (CHG) division, previously Abba Medix, is a wholly owned and fully licensed LP growing premium medical cannabis for medical patients and craft cannabis for the new recreational cannabis division. CHG has licensed the rights in Canada to Medicine Man Technologies’ commercial production methodologies for producing premium craft cannabis as well as the rights in Canada to the Success Nutrients™ line. The CHG division will also oversee the production of oils and extracts.

Canada House is also excited about the launch of its new retail division, Canada House Retail (CHR), to market CHG’s craft cannabis to the Canadian adult use market. Its first dispensary will be located in Edmonton. CHR will oversee the sales and marketing efforts of the seeds, genetics, and dried flower.

For further information, please contact: Boom Capital Markets Steve Low 647-620-5101 steve@boomcapitalmarkets.com Canada House Wellness Group Inc. Chris Churchill-Smith, CEO 514-313-0102 chris.smith@canadahouse.ca ___________________________________________________________________________ ABOUT CANADA HOUSE WELLNESS GROUP INC. Canada House is an experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy products and services through its clinics and licensed producer. Canada House is the parent company of Canada House Clinics Inc., Knalysis Technologies and Abba Medix Corp. For more information, please visit www.canadahouse.ca or www.sedar.com. Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.